SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

2/9/23 12:46:51 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $XENE alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 XENON PHARMACEUTICALS INC COMMON STOCK Cusip #98420N105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #98420N105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,690,829 Item 6: 0 Item 7: 4,690,829 Item 8: 0 Item 9: 4,690,829 Item 11: 7.500% Item 12: HC Cusip #98420N105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 4,690,829 Item 8: 0 Item 9: 4,690,829 Item 11: 7.500% Item 12: IN Item 1(a). Name of Issuer: XENON PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 200-3650 Gilmore Way Burnaby, British Columbia A1 V5G 48W Canada Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 98420N105 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 4,690,829 (b) Percent of Class: 7.500% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 4,690,829 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of XENON PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of XENON PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of XENON PHARMACEUTICALS INC at December 30, 2022. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January, 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $XENE alert in real time by email

Recent Analyst Ratings for

$XENE

Date	Price Target	Rating	Analyst
10/10/2024	$50.00	Outperform	Raymond James
10/1/2024	$53.00	Buy	H.C. Wainwright
1/4/2024	$62.00	Buy	Citigroup
12/8/2023	$63.00	Outperform	Robert W. Baird
10/24/2023		Overweight	Cantor Fitzgerald
4/25/2023	$58.00	Overweight	Cantor Fitzgerald
12/14/2022	$60.00	Buy	Goldman
12/12/2022		Outperform	Cowen

More analyst ratings

SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $XENE

$XENE Financials

Live finance-specific insights

Xenon Reports Q3 2024 Financial Results and Business Update

Xenon to Report Q3 2024 Financial Results on November 12, 2024

Xenon Reports Q2 2024 Financial Results and Business Update

$XENE Press Releases

Fastest customizable press release news feed in the world

Xenon to Present at Upcoming Investor Conferences

Xenon Reports Q3 2024 Financial Results and Business Update

Xenon to Report Q3 2024 Financial Results on November 12, 2024

$XENE SEC Filings

SEC Form 10-Q filed by Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form S-3ASR filed by Xenon Pharmaceuticals Inc.

$XENE Market Insights

Live Market Insights

$XENE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$XENE Leadership Updates

Live Leadership Updates

$XENE Large Ownership Changes

This live feed shows all institutional transactions in real time.

$XENE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target

Xenon Pharmaceuticals Presents Phase 2 X-NOVA Clinical Trial Data Of Azetukalner in Major Depressive Disorder At ASCP 2024 Annual Meeting

Needham Maintains Buy on Xenon Pharmaceuticals, Maintains $62 Price Target

SEC Form 4 filed by Patou Gary

SEC Form 4 filed by Machado Patrick

SEC Form 4 filed by Gover Justin D.

Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer

Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary

Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer

Amendment: SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

Raymond James resumed coverage on Xenon Pharmaceuticals with a new price target

H.C. Wainwright initiated coverage on Xenon Pharmaceuticals with a new price target

Citigroup initiated coverage on Xenon Pharmaceuticals with a new price target

Recent Analyst Ratings for
$XENE

$XENE
Financials

$XENE
Press Releases

$XENE
SEC Filings

$XENE
Market Insights

$XENE
Insider Trading

$XENE
Leadership Updates

$XENE
Large Ownership Changes

$XENE
Analyst Ratings